| 1. Accepted major perpetrators | 2. Rejected perpetrators | 3. Unclassifiable | 4. Full table |
erlotinib did not meet the criteria of being an inhibitor or inducer of CYP3A.
- Criteria not met: drugs evaluated in clinical PK interactions studies that do not meet the inclusion criteria (see Methods).
Footnotes and References
|a.||clinical PK interaction studies referred to in product information.|
|b.||likely to be a major inhibitor based on subjective evaluation (≥ 2-fold AUC increase or ≥ 50% decrease in clearance of in vivo CYP probe).|
|c.||likely to be a major inducer based on subjective evaluation (≥ 2-fold decrease in AUC or ≥ 50% increase in clearance of in vivo CYP probe).|
|1.||Hedaya MA, El-Afify DR, El-Maghraby GM. The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. Biopharmaceutics & Drug Disposition 2006; 27: 103-10.[PubMed]|
|2.||Wire MB, Shelton MJ, Studenberg S. Fosamprenavir - Clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clinical Pharmacokinetics 2006; 45: 137-68.[PubMed]|
|3.||Schellens JHM, Vanderwart JHF, Brugman M, Breimer DD. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design. Journal of Pharmacology and Experimental Therapeutics 1989; 249: 638-45.[PubMed]|
|4.||Abernethy DR, Greenblatt DJ, Morse DS, Shader RI. Interaction of propoxyphene with diazepam, alprazolam and lorazepam. British Journal of Clinical Pharmacology 1985; 19: 51-54.[PubMed]|
DisclaimerWARNING: While all efforts were put in to maintain the accuracy and currency of the information, it is possible that the knowledge and electronic tools may contain errors and inadequacy. Both Flinder's University and University of New South Wales are not liable to any damages or losses resulted from such circumstances. Clinical discretions are strongly advised at all times.